Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMNM NASDAQ:ONCT OTCMKTS:SEOVF NASDAQ:WVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMNMImmunome$22.19-4.6%$21.94$7.28▼$27.65$2.64B2.11860,907 shs609,103 shsONCTOncternal Therapeutics$0.53$0.53$0.53▼$7.17$1.56M1.1899,758 shsN/ASEOVFSernova Biotherapeutics$0.13-2.7%$0.12$0.09▼$0.17$50M0.8627,687 shs5,000 shsWVEWAVE Life Sciences$7.24-0.7%$9.65$5.02▼$21.73$1.40B-1.324.00 million shs4.24 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMNMImmunome-4.64%-3.27%+2.83%-10.81%+198.65%ONCTOncternal Therapeutics0.00%0.00%0.00%0.00%0.00%SEOVFSernova Biotherapeutics-2.72%+6.80%+15.00%+17.09%-13.44%WVEWAVE Life Sciences-0.69%+2.55%+1.97%-46.17%+11.13%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMNMImmunome$22.19-4.6%$21.94$7.28▼$27.65$2.64B2.11860,907 shs609,103 shsONCTOncternal Therapeutics$0.53$0.53$0.53▼$7.17$1.56M1.1899,758 shsN/ASEOVFSernova Biotherapeutics$0.13-2.7%$0.12$0.09▼$0.17$50M0.8627,687 shs5,000 shsWVEWAVE Life Sciences$7.24-0.7%$9.65$5.02▼$21.73$1.40B-1.324.00 million shs4.24 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMNMImmunome-4.64%-3.27%+2.83%-10.81%+198.65%ONCTOncternal Therapeutics0.00%0.00%0.00%0.00%0.00%SEOVFSernova Biotherapeutics-2.72%+6.80%+15.00%+17.09%-13.44%WVEWAVE Life Sciences-0.69%+2.55%+1.97%-46.17%+11.13%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMNMImmunome 2.91Moderate Buy$33.4550.76% UpsideONCTOncternal Therapeutics 0.00N/AN/AN/ASEOVFSernova Biotherapeutics 0.00N/AN/AN/AWVEWAVE Life Sciences 2.87Moderate Buy$27.50279.83% UpsideCurrent Analyst Ratings BreakdownLatest SEOVF, IMNM, WVE, and ONCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026WVEWAVE Life Sciences CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $24.005/4/2026IMNMImmunome Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/30/2026WVEWAVE Life Sciences Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$52.00 ➝ $43.004/29/2026WVEWAVE Life Sciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$50.00 ➝ $15.004/21/2026IMNMImmunome Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026WVEWAVE Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/14/2026WVEWAVE Life Sciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $18.003/27/2026WVEWAVE Life Sciences Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$38.00 ➝ $21.003/27/2026WVEWAVE Life Sciences Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$27.00 ➝ $13.003/25/2026WVEWAVE Life Sciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/25/2026WVEWAVE Life Sciences MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$22.00 ➝ $27.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMNMImmunome$6.94M362.11N/AN/A$5.75 per share3.86ONCTOncternal Therapeutics$790K1.97N/AN/A$10.19 per share0.05SEOVFSernova BiotherapeuticsN/AN/AN/AN/A($0.05) per shareN/AWVEWAVE Life Sciences$42.73M32.60N/AN/A$2.66 per share2.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMNMImmunome-$212.39M-$2.42N/AN/AN/AN/A-57.61%-52.39%5/11/2026 (Estimated)ONCTOncternal Therapeutics-$39.48M-$11.69N/AN/AN/A-1,599.95%-177.58%-131.30%N/ASEOVFSernova Biotherapeutics-$11.24M-$0.04N/AN/AN/AN/AN/A-761.41%6/11/2026 (Estimated)WVEWAVE Life Sciences-$204.38M-$1.06N/AN/AN/A-255.70%-56.76%-42.80%N/ALatest SEOVF, IMNM, WVE, and ONCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026IMNMImmunome-$0.60N/AN/AN/A$0.22 millionN/A4/29/2026Q1 2026WVEWAVE Life Sciences-$0.34-$0.13+$0.21-$0.13$8.45 million$38.25 million3/19/2026Q1 2026SEOVFSernova Biotherapeutics-$0.0073-$0.01-$0.0027-$0.01N/AN/A3/3/2026Q4 2025IMNMImmunome-$0.65-$0.75-$0.10-$0.75$0.79 millionN/A2/26/2026Q4 2025WVEWAVE Life Sciences-$0.28-$0.30-$0.02-$0.30$15.68 million$17.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIMNMImmunomeN/AN/AN/AN/AN/AONCTOncternal TherapeuticsN/AN/AN/AN/AN/ASEOVFSernova BiotherapeuticsN/AN/AN/AN/AN/AWVEWAVE Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMNMImmunomeN/A14.6914.69ONCTOncternal TherapeuticsN/A2.392.39SEOVFSernova BiotherapeuticsN/A0.030.03WVEWAVE Life SciencesN/A11.2611.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMNMImmunome44.58%ONCTOncternal Therapeutics16.05%SEOVFSernova BiotherapeuticsN/AWVEWAVE Life Sciences89.73%Insider OwnershipCompanyInsider OwnershipIMNMImmunome7.21%ONCTOncternal Therapeutics11.20%SEOVFSernova BiotherapeuticsN/AWVEWAVE Life Sciences23.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMNMImmunome40113.25 million105.09 millionOptionableONCTOncternal Therapeutics302.96 million2.63 millionNo DataSEOVFSernova BiotherapeuticsN/A377.64 millionN/ANot OptionableWVEWAVE Life Sciences240192.38 million146.25 millionOptionableSEOVF, IMNM, WVE, and ONCT HeadlinesRecent News About These CompaniesHC Wainwright Has Bullish Forecast for WVE Q2 EarningsMay 4, 2026 | americanbankingnews.comHC Wainwright Expects Higher Earnings for WAVE Life SciencesMay 4, 2026 | marketbeat.comCanaccord Genuity Reaffirms Their Buy Rating on Wave Life Sciences (WVE)May 3, 2026 | theglobeandmail.comA Look At Wave Life Sciences (WVE) Valuation After Sharp Year To Date Share Price DeclineMay 3, 2026 | finance.yahoo.comPictet Asset Management Holding SA Purchases 790,175 Shares of WAVE Life Sciences Ltd. $WVEMay 2, 2026 | marketbeat.comCanaccord Genuity Group Issues Pessimistic Forecast for WAVE Life Sciences (NASDAQ:WVE) Stock PriceMay 2, 2026 | americanbankingnews.comWAVE Life Sciences (NASDAQ:WVE) Upgraded to "Hold" at Wall Street ZenMay 2, 2026 | marketbeat.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Recommendation of "Moderate Buy" by AnalystsMay 2, 2026 | americanbankingnews.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Rating of "Moderate Buy" by AnalystsMay 2, 2026 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Given New $43.00 Price Target at Canaccord Genuity GroupApril 30, 2026 | marketbeat.comWAVE Life Sciences Ltd (WVE) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...April 29, 2026 | finance.yahoo.comWAVE Life Sciences (NASDAQ:WVE) Shares Down 7.6% - Here's What HappenedApril 29, 2026 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Posts Quarterly Earnings Results, Beats Expectations By $0.21 EPSApril 29, 2026 | marketbeat.comWAVE Life Sciences Q1 Earnings Call HighlightsApril 28, 2026 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Trading 5.5% Higher - Time to Buy?April 28, 2026 | marketbeat.comWave Life Sciences (WVE) Reports Q1 Loss, Beats Revenue EstimatesApril 28, 2026 | zacks.comWave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business UpdateApril 28, 2026 | globenewswire.comWAVE Life Sciences (NASDAQ:WVE) Shares Cross Below 50-Day Moving Average - Should You Sell?April 24, 2026 | marketbeat.comWAVE Life Sciences (WVE) Projected to Post Earnings on TuesdayApril 24, 2026 | marketbeat.comWave Life Sciences Ltd. (WVE) Sees Strong Buy Rating From AnalystsApril 23, 2026 | finance.yahoo.comWave Life Sciences Ltd. (WVE) Sees Strong Buy Rating From AnalystsApril 22, 2026 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSEOVF, IMNM, WVE, and ONCT Company DescriptionsImmunome NASDAQ:IMNM$22.19 -1.08 (-4.64%) Closing price 05/7/2026 04:00 PM EasternExtended Trading$22.14 -0.05 (-0.20%) As of 05/7/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.Oncternal Therapeutics NASDAQ:ONCTOncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.Sernova Biotherapeutics OTCMKTS:SEOVF$0.13 0.00 (-2.72%) As of 05/7/2026 10:12 AM EasternSernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.WAVE Life Sciences NASDAQ:WVE$7.24 -0.05 (-0.69%) Closing price 05/7/2026 04:00 PM EasternExtended Trading$7.30 +0.05 (+0.76%) As of 05/7/2026 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally IonQ Just Posted a Breakout Quarter—But 1 Problem Remains Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Nuts and Bolts AI Play Gains Momentum: Astera Labs Targets Raised Anheuser-Busch Stock Jumps as Volume Growth Signals Turnaround Light Speed Returns: Corning Cashes In on NVIDIA Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
